- Dong-E-E-Jiao reported a net income of 425.0 million yuan for the first quarter.
- The company generated a revenue of 1.72 billion yuan in the same period.
- Investor sentiment appears positive, with 19 buy ratings, 1 hold rating, and no sell ratings.
A look at Dong E E Jiaoco Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Dong E E Jiaoco Ltd A shows a promising long-term outlook. With high scores in Dividend, Growth, Resilience, and a solid score in Momentum, the company appears to be well-positioned for future sustainability and success. Although the Value score is not as high, the overall positive scores in other key areas indicate strong potential for growth and stability in the market.
Dong E E Jiaoco Ltd A, known for its focus on traditional Chinese medicine, health care products, health foods, and bio-medicine, also ventures into gelatin products manufacturing. The company’s stellar performance in Dividend, Growth, Resilience, and Momentum reflects its robust business model and the ability to weather market challenges, making it an attractive prospect for investors seeking long-term benefits.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
